BRPI0514196A - composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero - Google Patents

composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero

Info

Publication number
BRPI0514196A
BRPI0514196A BRPI0514196-6A BRPI0514196A BRPI0514196A BR PI0514196 A BRPI0514196 A BR PI0514196A BR PI0514196 A BRPI0514196 A BR PI0514196A BR PI0514196 A BRPI0514196 A BR PI0514196A
Authority
BR
Brazil
Prior art keywords
contraception
composition
compost
mammal
pharmaceutical kit
Prior art date
Application number
BRPI0514196-6A
Other languages
English (en)
Inventor
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Michael Anthony Marella
Jay Edward Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34993110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0514196A publication Critical patent/BRPI0514196A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSIçãO, USO DE COMPOSTO, KIT FARMACêUTICO, E, MéTODO DE CONTRACEPçãO DE UM MAMìFERO Derivados de pirrol-oxindol úteis como antagonistas de receptor de progesterona são proporcionados. Composições farmacêuticas contendo estes derivados são descritas, bem como o seu uso em contracepção e condições relacionadas com hormónio.
BRPI0514196-6A 2004-08-09 2005-07-06 composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero BRPI0514196A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59990004P 2004-08-09 2004-08-09
PCT/US2005/023782 WO2006023107A1 (en) 2004-08-09 2005-07-06 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0514196A true BRPI0514196A (pt) 2008-06-03

Family

ID=34993110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514196-6A BRPI0514196A (pt) 2004-08-09 2005-07-06 composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero

Country Status (20)

Country Link
US (1) US20060030615A1 (pt)
EP (1) EP1778222A1 (pt)
JP (1) JP2008509216A (pt)
KR (1) KR20070039925A (pt)
CN (1) CN101001625A (pt)
AR (1) AR049708A1 (pt)
AU (1) AU2005277879A1 (pt)
BR (1) BRPI0514196A (pt)
CA (1) CA2573310A1 (pt)
EC (1) ECSP077236A (pt)
GT (1) GT200500183A (pt)
IL (1) IL180955A0 (pt)
MX (1) MX2007001614A (pt)
NO (1) NO20070723L (pt)
PA (1) PA8638701A1 (pt)
PE (1) PE20060555A1 (pt)
RU (1) RU2007101304A (pt)
TW (1) TW200605882A (pt)
WO (1) WO2006023107A1 (pt)
ZA (1) ZA200701156B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
PA8638601A1 (es) 2004-07-07 2006-07-03 Wyeth Corp Regimenes y kits de progestina ciclica
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
CN101166521A (zh) 2005-04-28 2008-04-23 惠氏公司 通过湿制粒法制备包含微粒化他那普戈特的组合物
WO2006116514A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget, compositions, and methods of preparing the same
ES2340518T3 (es) * 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070404A1 (es) 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
WO2008021422A2 (en) * 2006-08-17 2008-02-21 Wyeth Process for the preparation of indolin-2-one derivatives useful as pr modulators
JP5460324B2 (ja) 2006-10-12 2014-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療剤としてのスピロ−オキシインドール化合物の使用
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
US20080312306A1 (en) * 2007-06-15 2008-12-18 Wyeth Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile
US20080319204A1 (en) * 2007-06-25 2008-12-25 Wyeth Process for the synthesis of progesterone receptor modulators
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
DK2350090T3 (en) 2008-10-17 2015-09-07 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047174A1 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
AU2005277879A1 (en) 2006-03-02
CN101001625A (zh) 2007-07-18
PE20060555A1 (es) 2006-06-26
GT200500183A (es) 2006-04-10
US20060030615A1 (en) 2006-02-09
TW200605882A (en) 2006-02-16
KR20070039925A (ko) 2007-04-13
JP2008509216A (ja) 2008-03-27
EP1778222A1 (en) 2007-05-02
WO2006023107A1 (en) 2006-03-02
RU2007101304A (ru) 2008-09-20
MX2007001614A (es) 2007-04-10
ECSP077236A (es) 2007-03-29
PA8638701A1 (es) 2006-06-02
ZA200701156B (en) 2008-08-27
CA2573310A1 (en) 2006-03-02
AR049708A1 (es) 2006-08-30
NO20070723L (no) 2007-05-07
IL180955A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0514196A (pt) composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0716171B8 (pt) composto, composição farmacêutica e uso de um composto
UY27760A1 (es) Nuevos derivados de pirrolidinio.
PE20100736A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
ECSP067113A (es) Compuestos amido y su uso como farmacéuticos
AR049262A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
BRPI0713565B8 (pt) processo para fabricação de uma forma de dosagem oral sólida
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
WO2006078629A3 (en) In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair
EP1994925A4 (en) PHARMACEUTICAL TAX FORMULATION, TAXAN SOLID-MATERIAL COMPOSITION, METHOD FOR PRODUCING TAXAN SOLID-MATERIAL COMPOSITION, COMPOSITION FOR SOLUBILIZING THE TAXAN SOLID-MATERIAL COMPOSITION, AND ELEMENT SET (KIT) FOR INJECTABLE TAX FORMULATION
BRPI0612189A2 (pt) composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
NO20092224L (no) Quiniklidinderivater av (hetero)arylcykloheptankarboksylsyre som muskarinreseptorantagonister
PA8623101A1 (es) Compuestos farmaceuticamente activos
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
NI201100176A (es) Nuevos derivados de compuestos de [3, 2-c] pirazol esteroidal con actividad glucocorticoide
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
TNSN05291A1 (en) Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]